Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Industrial biotech Bota Bio secures $100M in Series B financing

The company plans on using the funding to bolster its global operations and lab-to-pilot scale platform.

By Brian Buntz | July 29, 2021

Bota Bio logoDescribing itself as an “industrial biotechnology company,” Bota Bio has secured a total of $145 million in funding, thanks to a recent Series B funding round worth more than $100 million.

Bota Bio engineers microorganisms and biological components to make traditional manufacturing processes more sustainable. “One part of Bota Bio’s pharmaceutical business is focused on helping manufacturers of active pharmaceutical ingredients (APIs) make the transition from chemical manufacturing to biological manufacturing,” said the company’s co-founder and CEO, Cheryl Cui. Acknowledging that understand “many traditional chemistry products are very inexpensive,” Cui adds that many API manufacturers are looking to make their processes more sustainable. “Boat Bio can help with that,” she explained.

The company’s technology platform, the Bota Freeway, “takes advantage of currently available technologies and leverages a proprietary mix of digital and lab automation tools,” Cui said. The platform enables its “clients to design anywhere and receive high-throughput screening data 50% faster than existing technology stacks,” she added.

Sequoia Capital China led the Series B financing funding round. Other backers include previous investors Matrix Partners China, Source Code Capital, Sherpa Healthcare Partners and 5Y Capital.

Cheryl Cui

Cheryl Cui

The company also previously received a strategic investment led by BASF Venture Capital (BVC), the venture arm of BASF Group.
Bota Bio plans on using its most recent funding to boost its global operations and develop Bota Bio’s lab-to-pilot scale platform. The company says the platform will ultimately facilitate the deployment of its product pipeline, including pharmaceuticals and consumer goods, food, and nutrition products.

The company recently expanded the design part of the design-test-build-Learn cycle to include downstream processing. “This was important to Bota because it means we can be a bit ‘microbe-agnostic’ and find the best solution for each of our clients,” Cui said. “We believe it gives our clients the ability to be more agile compared to traditional chemical processes.”

Because some companies relying on chemistry for manufacturing “do not always understand the benefits of using biology,” Cui said Bota Bio also works “as interpreters (or translators) between traditional manufacturers and our next-generation biological processes.”

A team of scientists and industry veterans founded the company in 2019.

Given the rapid evolution of synthetic biology and the versatility of its platform, Bota Bio can improve the efficiencies of manufacturing enzymes and difficult-to-manufacture proteins, according to Cui. Such enzymes and proteins “comprise the top-selling drugs on the market,” she added.
Cui notes that the pandemic has elevated the importance of biology in society, giving rise to a variety of COVID-19 vaccines. “Manufacturers are becoming increasingly aware that they need to secure supply chains while also increasing the sustainability of their manufacturing,” Cui said. “Bota Bio is well-positioned to make an impact on biomanufacturing, and we are lucky to have the support of such a great set of investors.”

Cui was trained at Harvard University and MIT. Its CTO, Chia-Hong Tsai, was trained at Michigan State.

Other executives have academic and industrial experience at prominent universities such as Harvard and companies such as Teva, Bayer, Gingko Bioworks and Codexis.

The company’s scientific advisory board includes researchers from Caltech; the University of Texas, Austin; MIT and Texas A&M University.


Filed Under: Drug Discovery
Tagged With: 5Y Capital, Bota Bio, Matrix Partners China, Sequoia Capital China, Sherpa Healthcare Partners, Source Code Capital, venture capital
 

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Related Articles Read More >

lab microscope
Accelerating R&D with FAIR data
Kallyope
Kallyope’s focus on the gut-brain axis yields a diverse portfolio
Axcella
Axcella touts positive results from Phase 2a long COVID study
artificial intelligence
Defining complexity: A framework to identify complex clinical trials and set them up for success

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Medtech100 Index
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50